Bharat Bio successfully completes Phase III trials of new oral cholera vaccine Hillchol

Bharat Biotech's oral cholera vaccine, Hillchol, has demonstrated successful Phase III clinical trial results, proving effective against both Ogawa and Inaba serotypes. The vaccine exhibited a significant rise in vibriocidal antibodies and maintained a strong safety profile across all age groups. With production capacity of 200 million doses, Hillchol can address the global cholera crisis and vaccine shortages.

from India News | Latest India News Headlines Today and Live Updates from India - Times of India https://ift.tt/eioaYcX